Oncotarget is a journal that operates under the principles of the Committee on Publication Ethics. The international journal mainly targets on the research of the primary cause of all sorts of cancer. It uses the peer review approach to providing accurate information to the targeted audience. It also researches on treatment and therapies, aimed at improving cancer patient’s care. Oncotarget also looks into results found following new management programs and therapies adopted focusing on the perspective of cancer patients regarding adherence, satisfaction, and quality of life.
Current Therapies Improvement
The journal further seeks to understand the currently existing therapies and treatments by exploring the evidence behind them. It defines their utilization with an aim to drive their acceptance by both cancer patients and physicians. Oncotarget also seeks to improve these therapies and treatments with an ultimate goal of improving results upon their use.
Oncotarget is a free to access journal that hosts different disciplines of science and research. Its papers are published in weekly issues on an online platform. These papers can, however, be printed on exceptional requests. Oncotarget’s primary goal is to avail science research results and discoveries to a wide audience in the shortest time possible. The journal also seeks to link different areas of biomedical sciences by getting rid of the borders between them. Their ultimate goal is to use these discoveries in fighting diseases to eventually achieve a disease-free world.
Moving Beyond Oncology
Following the impeccable leadership of top and reputable scientists, Oncotarget has managed to gear each researcher in contributing to the improvement and progress of science. This great achievement led Oncotarget in accepting subjects that go beyond oncology. It has so far specialized in immunology, neuroscience, cell death, autophagy, circadian rhythm, pathology, and neurotarget. Download output styles at Endnote.com
More About Oncotarget
Oncotarget existence dates back to the year 2010. It is led by chief editors Oncologist Mikhail Blagosklonny and Andrei V. Gudkov, who is an Oncologist, College Professor, and a Cancer Researcher. The journal has continuously grown and improved its performance. This has seen some of its members receive the highest price in the field dubbed the Breakthrough Prize. The journal is successfully published by Impact Journals and is funded by Gordon Research Conference.